EUVIMEDEUVIMED entdecken
Crossref

Preclinical evaluation of 18F-labeled tozadenant analogs as potential PET tracers for cerebral A2A adenosine receptors

F. Wedekind, M. Lang, S. Humpert, D. Schneider, A. Drechsel, S. Klein, F. M. Mottaghy, R. Tolba, B. Neumaier, A. Drzezga, A. Bauer

Nuklearmedizin - NuclearMedicine · 01.03.2024 · 63 (02) · 151-152

DOI: 10.1055/s-0044-1782466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.03.2024. Verfasst von F. Wedekind und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Wedekind, F., Lang, M., Humpert, S., Schneider, D., Drechsel, A., Klein, S., Mottaghy, F. M., Tolba, R., Neumaier, B., Drzezga, A., & Bauer, A. (2024). Preclinical evaluation of 18F-labeled tozadenant analogs as potential PET tracers for cerebral A2A adenosine receptors. Nuklearmedizin - NuclearMedicine, 63(02), 151-152. https://doi.org/10.1055/s-0044-1782466

Vancouver

Wedekind F, Lang M, Humpert S, Schneider D, Drechsel A, Klein S, et al. Preclinical evaluation of 18F-labeled tozadenant analogs as potential PET tracers for cerebral A2A adenosine receptors. Nuklearmedizin - NuclearMedicine. 2024;63(02):151-152. doi:10.1055/s-0044-1782466

BibTeX
@article{Wedekind2024,
  author = {Wedekind, F. and Lang, M. and Humpert, S. and Schneider, D. and Drechsel, A. and Klein, S. and Mottaghy, F. M. and Tolba, R. and Neumaier, B. and Drzezga, A. and Bauer, A.},
  title = {Preclinical evaluation of 18F-labeled tozadenant analogs as potential PET tracers for cerebral A2A adenosine receptors},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2024},
  volume = {63},
  number = {02},
  pages = {151--152},
  doi = {10.1055/s-0044-1782466}
}
Kostenlos starten →